

The PI3K/AKT/mTOR pathway in breast cancer: targets

Therapeutic Advances in Medical Oncology

6, 154-166

DOI: [10.1177/1758834014530023](https://doi.org/10.1177/1758834014530023)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-8.	0.5	12
2	Overexpression of sorcin in multidrug-resistant human breast cancer. <i>Oncology Letters</i> , 2014, 8, 2393-2398.	0.8	18
3	Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells. <i>Cellular Signalling</i> , 2014, 26, 2782-2792.	1.7	39
4	PIK3CA Mutations in Small Bowel Adenocarcinoma. <i>Tumori</i> , 2015, 101, e85-e87.	0.6	2
5	CaCO ₃ /CaIP6 composite nanoparticles effectively deliver AKT1 small interfering RNA to inhibit human breast cancer growth. <i>International Journal of Nanomedicine</i> , 2015, 10, 4255.	3.3	14
6	PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4631.	2.0	6
7	Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions. <i>Current Molecular Pharmacology</i> , 2015, 7, 4-21.	0.7	23
8	Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor positive advanced breast cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 3629.	1.0	13
9	Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells. <i>Oncology Research</i> , 2015, 22, 193-201.	0.6	29
10	From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 153, 45-53.	1.2	47
11	Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway. <i>BMC Cancer</i> , 2015, 15, 958.	1.1	105
12	12-Deoxyphorbol 13-palmitate inhibits the expression of VEGF and HIF-1 α in MCF-7 cells by blocking the PI3K/Akt/mTOR signaling pathway. <i>Oncology Reports</i> , 2015, 34, 1755-1760.	1.2	29
13	Calycosin and Genistein Induce Apoptosis by Inactivation of HOTAIR/p-Akt Signaling Pathway in Human Breast Cancer MCF-7 Cells. <i>Cellular Physiology and Biochemistry</i> , 2015, 35, 722-728.	1.1	117
14	Impact of lower concentrations of phytoestrogens on the effects of estradiol in breast cancer cells. <i>Climacteric</i> , 2015, 18, 574-581.	1.1	16
15	PI3K/Akt signaling in osteosarcoma. <i>Clinica Chimica Acta</i> , 2015, 444, 182-192.	0.5	262
16	The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 105-118.	1.1	125
17	Curcumin Promotes Cell Cycle Arrest and Inhibits Survival of Human Renal Cancer Cells by Negative Modulation of the PI3K/AKT Signaling Pathway. <i>Cell Biochemistry and Biophysics</i> , 2015, 73, 681-686.	0.9	39
18	Molecular and diagnostic features of apocrine breast lesions. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1011-1022.	1.5	14

#	ARTICLE	IF	CITATIONS
19	Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1045-1058.	1.9	1
20	Changing Treatment Paradigms in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 528.	3.4	88
21	Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 153, 35-44.	1.2	90
22	MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy. <i>Cell Reports</i> , 2015, 11, 1358-1366.	2.9	40
23	Phosphatidylinositol-3-kinase as a putative target for anticancer action of clotrimazole. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 62, 132-141.	1.2	13
24	A multi-targeted approach to suppress tumor-promoting inflammation. <i>Seminars in Cancer Biology</i> , 2015, 35, S151-S184.	4.3	95
25	Ovariectomy is associated with metabolic impairments and enhanced mammary tumor growth in MKR mice. <i>Journal of Endocrinology</i> , 2015, 227, 143-151.	1.2	10
26	Localized experimental bone metastasis drives osteolysis and sensory hypersensitivity at distant non-tumor-bearing sites. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 9-20.	1.1	10
27	Advances in small-molecule drug discovery for triple-negative breast cancer. <i>Future Medicinal Chemistry</i> , 2015, 7, 2019-2039.	1.1	14
28	Differential expression of epithelial-mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 45-55.	1.1	32
29	The Genome Conformation As an Integrator of Multi-Omic Data: The Example of Damage Spreading in Cancer. <i>Frontiers in Genetics</i> , 2016, 7, 194.	1.1	22
30	FLIPL is critical for aerobic glycolysis in hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 79.	3.5	17
31	Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. <i>Frontiers in Pharmacology</i> , 2016, 7, 395.	1.6	131
32	Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 182-190.	0.8	29
33	The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures. <i>Cancer Drug Discovery and Development</i> , 2016, , 109-124.	0.2	0
34	Discovery of 4-(Piperazin-1-yl)pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors. <i>Archiv Dgr Pharmazie</i> , 2016, 349, 356-362.	2.1	5
35	The PI3K Pathway: Background and Treatment Approaches. <i>Breast Care</i> , 2016, 11, 398-404.	0.8	28
36	Creating chemotherapeutic-resistant breast cancer cell lines: advances and future perspectives. <i>Future Oncology</i> , 2016, 12, 1517-1527.	1.1	9

#	ARTICLE	IF	CITATIONS
38	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2016, , 535-573.		0
39	Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2159-2171.	1.2	23
40	Effects of mutations in Wnt/ β -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activityâ€”Diverse effects on cell growth, metabolism and cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2942-2976.	1.9	137
41	Regulation of gene expression in human cancers by TRIM24. <i>Drug Discovery Today: Technologies</i> , 2016, 19, 57-63.	4.0	36
42	A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. <i>BMC Medical Genomics</i> , 2016, 9, 51.	0.7	42
43	Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. <i>Annals of Oncology</i> , 2016, 27, 2059-2066.	0.6	79
44	Stiffness of the microenvironment upregulates ERBB2 expression in 3D cultures of MCF10A within the range of mammographic density. <i>Scientific Reports</i> , 2016, 6, 28987.	1.6	15
45	Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S12443.	0.6	8
46	PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. <i>Journal of Translational Medicine</i> , 2016, 14, 67.	1.8	42
47	Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 91-101.	1.0	26
48	Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 601-610.	1.8	26
49	Overexpression of Hexokinase 1 as a poor prognosticator in human colorectal cancer. <i>Tumor Biology</i> , 2016, 37, 3887-3895.	0.8	27
50	Pluripotency transcription factors in lung cancerâ€”a review. <i>Tumor Biology</i> , 2016, 37, 4241-4249.	0.8	24
51	mTORC1 directly phosphorylates and activates ER β upon estrogen stimulation. <i>Oncogene</i> , 2016, 35, 3535-3543.	2.6	70
52	Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2 β and ER+HER2+) breast cancers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 170, 65-74.	1.2	26
53	Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies. <i>Journal of Natural Products</i> , 2017, 80, 932-952.	1.5	24
54	Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles. <i>Endocrine-Related Cancer</i> , 2017, 24, R81-R97.	1.6	21
55	A novel resveratrolâ€”salinomycin combination sensitizes ER-positive breast cancer cells to apoptosis. <i>Pharmacological Reports</i> , 2017, 69, 788-797.	1.5	24

#	ARTICLE	IF	CITATIONS
56	Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 487-497.	1.2	33
57	Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer. <i>Future Oncology</i> , 2017, 13, 1371-1384.	1.1	5
58	Enrichment of PI3K-AKT/mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4919-4928.	3.2	74
59	Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. <i>Genome Medicine</i> , 2017, 9, 40.	3.6	16
60	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017, 34, 119.	1.2	34
61	DNA Mutations May Not Be the Cause of Cancer. <i>Oncology and Therapy</i> , 2017, 5, 85-101.	1.0	48
62	Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 39-45.	2.5	13
63	Citrus flavonoid naringenin reduces mammary tumor cell viability, adipose mass, and adipose inflammation in obese ovariectomized mice. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600934.	1.5	44
64	Identification of natural allosteric inhibitor for Akt1 protein through computational approaches and in vitro evaluation. <i>International Journal of Biological Macromolecules</i> , 2017, 96, 200-213.	3.6	12
65	Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. <i>Cellular Signalling</i> , 2017, 30, 154-161.	1.7	32
66	Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?. <i>Drug Safety</i> , 2017, 40, 211-228.	1.4	11
67	Decreased levels of sRAGE in follicular fluid from patients with PCOS. <i>Reproduction</i> , 2017, 153, 285-292.	1.1	21
68	Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2017, 46, 158-181.	4.3	57
69	MicroRNA-218-5p as a Potential Target for the Treatment of Human Osteoarthritis. <i>Molecular Therapy</i> , 2017, 25, 2676-2688.	3.7	50
70	Controlling Directed Protein Interaction Networks in Cancer. <i>Scientific Reports</i> , 2017, 7, 10327.	1.6	55
71	Association of breast cancer risk and the mTOR pathway in women of African ancestry in the Root™ Consortium. <i>Carcinogenesis</i> , 2017, 38, 789-796.	1.3	6
72	Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 2862-2866.	0.8	6
73	Whey Protein Concentrate Renders MDA-MB-231 Cells Sensitive to Rapamycin by Altering Cellular Redox State and Activating GSK3 ^β /mTOR Signaling. <i>Scientific Reports</i> , 2017, 7, 15976.	1.6	16

#	ARTICLE	IF	CITATIONS
74	Revisiting the IGF-1R as a breast cancer target. <i>Npj Precision Oncology</i> , 2017, 1, .	2.3	75
75	Transcription factor-associated combinatorial epigenetic pattern reveals higher transcriptional activity of TCF7L2-regulated intragenic enhancers. <i>BMC Genomics</i> , 2017, 18, 375.	1.2	13
76	Identifying gene-gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts. <i>Human Genetics</i> , 2017, 136, 165-178.	1.8	11
77	Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway. <i>Medical Science Monitor</i> , 2017, 23, 4182-4191.	0.5	22
78	Biomarkers From Systems Biology and Omics-Studies. , 2017, , 67-79.		0
79	Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer. <i>Journal of Breast Cancer</i> , 2017, 20, 321.	0.8	21
80	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 85.	1.8	25
81	Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth. <i>Frontiers in Endocrinology</i> , 2017, 8, 173.	1.5	10
82	Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients. <i>PLoS ONE</i> , 2017, 12, e0174022.	1.1	12
83	Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	1.4	31
84	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5491-5524.	1.0	56
85	Determination of the Relative Efficacy of Eicosapentaenoic Acid and Docosahexaenoic Acid for Anti-Cancer Effects in Human Breast Cancer Models. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2607.	1.8	30
86	Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient. <i>Cureus</i> , 2017, 9, e1408.	0.2	10
87	The influence of matrix stiffness on the behavior of brain metastatic breast cancer cells in a biomimetic hyaluronic acid hydrogel platform. <i>Journal of Biomedical Materials Research - Part A</i> , 2018, 106, 1832-1841.	2.1	36
88	Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 499-506.	1.1	14
89	SRT1720, a potential sensitizer for radiotherapy and cytotoxicity effects of NVB-BEZ235 in metastatic breast cancer cells. <i>Pathology Research and Practice</i> , 2018, 214, 889-895.	1.0	17
90	The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells. <i>Breast Cancer Research</i> , 2018, 20, 16.	2.2	88
91	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. <i>Npj Precision Oncology</i> , 2018, 2, 7.	2.3	107

#	ARTICLE	IF	CITATIONS
92	Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 29-36.	2.0	35
93	Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. <i>Clinical Cancer Research</i> , 2018, 24, 395-406.	3.2	18
94	Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. <i>Cancer Treatment Reviews</i> , 2018, 62, 110-122.	3.4	273
95	The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. <i>PeerJ</i> , 2018, 6, e5092.	0.9	36
96	Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880850.	1.4	30
97	mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. <i>Npj Breast Cancer</i> , 2018, 4, 36.	2.3	20
98	Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis. <i>Scientific Reports</i> , 2018, 8, 16679.	1.6	29
99	Statins attenuate outgrowth of breast cancer metastases. <i>British Journal of Cancer</i> , 2018, 119, 1094-1105.	2.9	64
100	MiR-3188 Inhibits Non-small Cell Lung Cancer Cell Proliferation Through FOXO1-Mediated mTOR-p-PI3K/AKT-c-JUN Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2018, 9, 1362.	1.6	18
101	Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer. <i>BMC Systems Biology</i> , 2018, 12, 130.	3.0	7
102	C16- ϵ -ceramide and sphingosine-1-phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation. <i>Oncology Reports</i> , 2018, 40, 2977-2987.	1.2	9
103	Resveratrol provides neuroprotection by regulating the JAK2/STAT3/PI3K/AKT/mTOR pathway after stroke in rats. <i>Genes and Diseases</i> , 2018, 5, 245-255.	1.5	164
104	E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer. <i>Scientific Reports</i> , 2018, 8, 15454.	1.6	55
105	Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	9
106	Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer. <i>Applied Biochemistry and Biotechnology</i> , 2018, 186, 1074-1089.	1.4	31
107	Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. <i>International Journal of Oncology</i> , 2018, 52, 2051-2060.	1.4	18
108	Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. <i>PLoS ONE</i> , 2018, 13, e0197422.	1.1	75
109	High collagen density augments mTOR-dependent cancer stem cells in ER \pm mammary carcinomas, and increases mTOR-independent lung metastases. <i>Cancer Letters</i> , 2018, 433, 1-9.	3.2	29

#	ARTICLE	IF	CITATIONS
110	GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling. <i>Scientific Reports</i> , 2018, 8, 9511.	1.6	37
111	Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. <i>Cancer Biology and Therapy</i> , 2018, 19, 879-886.	1.5	22
112	Transcriptional repression of human epidermal growth factor receptor 2 by $\text{Cl}^{\text{sup}}\hat{\text{a}}^{\text{sup}}/\text{H}^{\text{sup}}+\text{⁺}$ transporter inhibition in human breast cancer cells. <i>Cancer Science</i> , 2018, 109, 2781-2791.	1.7	16
113	Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K $\hat{\text{I}}^{\text{sup}}$ -selective inhibitor CYH33 in breast cancer. <i>Cancer Letters</i> , 2018, 433, 273-282.	3.2	15
114	A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 12.	3.5	19
115	Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification. <i>Cancer Research</i> , 2018, 78, 6001-6010.	0.4	64
116	Hyaluronic Acid-Decorated Chitosan Nanoparticles for CD44-Targeted Delivery of Everolimus. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2310.	1.8	58
117	Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Targeted Oncology</i> , 2019, 14, 1-12.	1.7	12
118	Weighted Fused Pathway Graphical Lasso for Joint Estimation of Multiple Gene Networks. <i>Frontiers in Genetics</i> , 2019, 10, 623.	1.1	11
119	Targeting the phosphoinositide 3-kinase/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells. <i>Molecular Biology Reports</i> , 2019, 46, 4809-4816.	1.0	13
120	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
121	Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy. , 2019, , 449-462.		0
122	Targeting cellular cholesterol for anticancer therapy. <i>FEBS Journal</i> , 2019, 286, 4192-4208.	2.2	39
123	In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data. <i>Scientific Reports</i> , 2019, 9, 8949.	1.6	66
124	Gene relevance based on multiple evidences in complex networks. <i>Bioinformatics</i> , 2020, 36, 865-871.	1.8	6
125	Tamoxifen and Sulphoraphane for the breast cancer management: A synergistic nanomedicine approach. <i>Medical Hypotheses</i> , 2019, 132, 109379.	0.8	20
126	Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer. <i>Cancer Genetics</i> , 2019, 239, 36-45.	0.2	14
127	PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. <i>Drug Discovery Today</i> , 2019, 24, 2181-2191.	3.2	170

#	ARTICLE	IF	CITATIONS
128	Investigation of Phospholipase C β 1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4721.	1.8	5
129	Bayesian Inference Identifies Combination Therapeutic Targets in Breast Cancer. <i>IEEE Transactions on Biomedical Engineering</i> , 2019, 66, 2684-2692.	2.5	26
130	Membrane metalloendopeptidase mediates cellular senescence induced by oncogenic PI3KCA ^{H1047R} accompanied with pro-tumorigenic secretome. <i>International Journal of Cancer</i> , 2019, 145, 817-829.	2.3	8
131	Expression analysis of miR-100 and selected genes from mTOR pathway in breast cancer patients. <i>Meta Gene</i> , 2019, 21, 100577.	0.3	1
132	HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment. <i>Cell Cycle</i> , 2019, 18, 1513-1522.	1.3	15
133	PI3K Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction. <i>Journal of the American Heart Association</i> , 2019, 8, e010961.	1.6	15
134	SP-8356, a (1S)-(E)-verbenone derivative, exerts in vitro and in vivo anti-breast cancer effects by inhibiting NF- κ B signaling. <i>Scientific Reports</i> , 2019, 9, 6595.	1.6	17
135	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	1.1	26
136	Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1827.	1.8	14
137	Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 195-206.	1.0	13
138	The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways. <i>Cell Calcium</i> , 2019, 79, 80-88.	1.1	46
139	Encircling the regions of the pharmacogenomic landscape that determine drug response. <i>Genome Medicine</i> , 2019, 11, 17.	3.6	14
140	Fomes fomentarius Ethanol Extract Exerts Inhibition of Cell Growth and Motility Induction of Apoptosis via Targeting AKT in Human Breast Cancer MDA-MB-231 Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1147.	1.8	15
142	Multilayer network analysis of miRNA and protein expression profiles in breast cancer patients. <i>PLoS ONE</i> , 2019, 14, e0202311.	1.1	8
143	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3374-3383.	3.2	57
144	Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells. <i>Clinical Cancer Research</i> , 2019, 25, 2900-2914.	3.2	24
145	Discovery, synthesis and molecular corroborations of medicinally important novel pyrazoles; drug efficacy determinations through in silico, in vitro and cytotoxicity validations. <i>Bioorganic Chemistry</i> , 2019, 86, 410-419.	2.0	18
146	Identification of Breast Cancer Subtype Specific MicroRNAs Using Survival Analysis to Find Their Role in Transcriptomic Regulation. <i>Frontiers in Genetics</i> , 2019, 10, 1047.	1.1	16

#	ARTICLE	IF	CITATIONS
147	Contribution of the unfolded protein response to breast and prostate tissue homeostasis and its significance to cancer endocrine response. <i>Carcinogenesis</i> , 2019, 40, 203-215.	1.3	15
148	Benefitâ€‘risk profile of black cohosh (isopropanolic <i>Cimicifuga racemosa</i> extract) with and without St Johnâ€™s wort in breast cancer patients. <i>Climacteric</i> , 2019, 22, 339-347.	1.1	25
149	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 29-42.	1.1	11
150	Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 489-497.	1.1	118
151	Systemic Treatment of HER2-Negative Metastatic Breast Cancer. , 2019, , 483-508.		0
152	Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: A new look at hallmarks of breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 10080-10100.	2.0	208
153	Long-term exposure to extremely low-dose of nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induce non-malignant breast epithelial cell transformation through activation of the $\alpha 9$ nicotinic acetylcholine receptor-mediated signaling pathway. <i>Environmental Toxicology</i> , 2019, 34, 73-82.	2.1	18
154	Peptide Based Imaging Agents for HER2 Imaging in Oncology. <i>Molecular Imaging</i> , 2020, 19, 153601212096025.	0.7	11
155	Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer. <i>BMC Cancer</i> , 2020, 20, 676.	1.1	8
156	Profilin choreographs actin and microtubules in cells and cancer. <i>International Review of Cell and Molecular Biology</i> , 2020, 355, 155-204.	1.6	32
157	Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with $\beta 1$ -Integrin Emerges as a Key Factor for Breast Cancer Chemosensitization upon Collagen Type 1 Binding. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4956.	1.8	13
158	Vascular endothelial growth factor encoded by Parapoxviruses can regulate metabolism and survival of triple negative breast cancer cells. <i>Cell Death and Disease</i> , 2020, 11, 996.	2.7	4
159	New horizons in benzothiazole scaffold for cancer therapy: Advances in bioactivity, functionality, and chemistry. <i>Applied Materials Today</i> , 2020, 20, 100783.	2.3	25
160	Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer. <i>Cancer Communications</i> , 2020, 40, 422-434.	3.7	6
161	Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. <i>Targeted Oncology</i> , 2020, 15, 723-732.	1.7	6
162	Cancer subtype classification and modeling by pathway attention and propagation. <i>Bioinformatics</i> , 2020, 36, 3818-3824.	1.8	28
163	Cotargeting <i>BET</i> proteins overcomes resistance arising from <i>PI3K</i> / <i>mTOR</i> blockade-induced protumorigenic senescence in colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 2824-2837.	2.3	6
164	A Systematic Review of the Prevalence and Diagnostic Workup of <i>PIK3CA</i> Mutations in HR+/HER2â€‘ Metastatic Breast Cancer. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-16.	0.6	33

#	ARTICLE	IF	CITATIONS
165	p-TSA.H ₂ O mediated one-pot, multi-component synthesis of isatin derived imidazoles as dual-purpose drugs against inflammation and cancer. <i>Bioorganic Chemistry</i> , 2020, 102, 104046.	2.0	17
166	The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer. <i>Oncogene</i> , 2020, 39, 3588-3603.	2.6	24
167	Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets. <i>Pathology Research and Practice</i> , 2020, 216, 152874.	1.0	8
168	Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 ⁺ Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations. <i>Clinical Breast Cancer</i> , 2020, 20, e439-e449.	1.1	10
169	Is Lactate an Oncometabolite? Evidence Supporting a Role for Lactate in the Regulation of Transcriptional Activity of Cancer-Related Genes in MCF7 Breast Cancer Cells. <i>Frontiers in Oncology</i> , 2019, 9, 1536.	1.3	63
170	Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. <i>Prostate</i> , 2020, 80, 412-423.	1.2	9
171	Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms – an update on the evidence. <i>Climacteric</i> , 2021, 24, 109-119.	1.1	22
172	Obesity-related protein biomarkers for predicting breast cancer risk: an overview of systematic reviews. <i>Breast Cancer</i> , 2021, 28, 25-39.	1.3	14
173	Landscape of clinically actionable mutations in breast cancer – A cohort study TM . <i>Translational Oncology</i> , 2021, 14, 100877.	1.7	4
174	miR-152/TNS1 axis inhibits non-small cell lung cancer progression through Akt/mTOR/RhoA pathway. <i>Bioscience Reports</i> , 2021, 41, .	1.1	11
175	siRNA Knockdown of REDD1 Facilitates Aspirin-Mediated Dephosphorylation of mTORC1 Target 4E-BP1 in MDA-MB-468 Human Breast Cancer Cell Line. <i>Cancer Management and Research</i> , 2021, Volume 13, 1123-1133.	0.9	6
176	A Network Pharmacology Study on the Molecular Mechanisms of FDY003 for Breast Cancer Treatment. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-18.	0.5	6
177	The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer – A Preliminary Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2061.	1.8	8
178	IP6K2 predicts favorable clinical outcome of primary breast cancer. <i>Molecular and Clinical Oncology</i> , 2021, 14, 94.	0.4	2
179	Differential methylation and expression patterns of microRNAs in relation to breast cancer subtypes among American women of African and European ancestry. <i>PLoS ONE</i> , 2021, 16, e0249229.	1.1	8
180	High expression levels of centromere protein A plus upregulation of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway affect chemotherapy response and prognosis in patients with breast cancer. <i>Oncology Letters</i> , 2021, 21, 410.	0.8	17
181	Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer. <i>Frontiers in Endocrinology</i> , 2021, 12, 599586.	1.5	44
182	Cell specific tumor suppressor effect of Hsa-miR-1226-3p through downregulation of HER2, PIK3R2, and AKT1 genes. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 134, 105965.	1.2	10

#	ARTICLE	IF	CITATIONS
183	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesisâ€”New insight and futuristic vision. <i>International Journal of Biological Macromolecules</i> , 2021, 180, 739-752.	3.6	39
184	Stem cell therapy: A paradigm shift in breast cancer treatment. <i>World Journal of Stem Cells</i> , 2021, 13, 841-860.	1.3	8
185	Collagen XVII inhibits breast cancer cell proliferation and growth through deactivation of the AKT/mTOR signaling pathway. <i>PLoS ONE</i> , 2021, 16, e0255179.	1.1	16
186	Single-cell immunoblotting resolves estrogen receptor- α isoforms in breast cancer. <i>PLoS ONE</i> , 2021, 16, e0254783.	1.1	5
187	Efficacy and safety of long-term sirolimus use as part of multidisciplinary care in a pediatric patient with CLOVES syndrome: Case report. <i>Translational Science of Rare Diseases</i> , 2022, 6, 25-32.	1.6	0
188	COMPREHENSIVE REVIEW ON ETIOPATHOGENESIS, TREATMENT AND EMERGING THERAPIES OF BREAST CANCER. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 20-33.	0.3	0
189	Identification of a novel inhibitor of liver cancer cell invasion and proliferation through regulation of Akt and Twist1. <i>Scientific Reports</i> , 2021, 11, 16765.	1.6	3
190	Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial. <i>Frontiers in Immunology</i> , 2021, 12, 669965.	2.2	16
191	Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer. <i>Cancers</i> , 2021, 13, 4685.	1.7	34
193	<i>Mangifera indica</i> (Mango): A Promising Medicinal Plant for Breast Cancer Therapy and Understanding Its Potential Mechanisms of Action. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 471-503.	1.0	19
194	Transcriptional alterations of protein coding and noncoding RNAs in triple negative breast cancer in response to DNA methyltransferases inhibition. <i>Cancer Cell International</i> , 2021, 21, 515.	1.8	5
195	Network Pharmacology-Based Dissection of the Comprehensive Molecular Mechanisms of the Herbal Prescription FDY003 Against Estrogen Receptor-Positive Breast Cancer. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110443.	0.2	1
196	Circadian PERFORMANCE in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression. <i>Npj Breast Cancer</i> , 2021, 7, 118.	2.3	3
197	Molecular Mechanisms Underlying Breast Cancer and Role of Plant Products in Targeted Therapy. , 2021, , 295-351.		3
198	Antitumour immunity regulated by aberrant ERBB family signalling. <i>Nature Reviews Cancer</i> , 2021, 21, 181-197.	12.8	141
199	Phytotherapy for breast cancer. , 2021, , 129-163.		5
200	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342199585.	0.6	22
201	A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100457.	0.7	5

#	ARTICLE	IF	CITATIONS
203	In silico molecular docking studies and MM/GBSA analysis of coumarin-carbonodithioate hybrid derivatives divulge the anticancer potential against breast cancer. Beni-Suef University Journal of Basic and Applied Sciences, 2020, 9, .	0.8	58
204	P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2017, 12, e0170302.	1.1	5
205	Functional role of vitronectin in breast cancer. PLoS ONE, 2020, 15, e0242141.	1.1	16
206	Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer. Uspeshi Molekularnoj Onkologii, 2018, 5, 40-50.	0.1	6
207	Lactobacilli Differentially Modulate mTOR and Wnt/ β -Catenin Pathways in Different Cancer Cell Lines. Iranian Journal of Cancer Prevention, 2016, In Press, e5369.	0.7	28
208	miR-623 suppresses cell proliferation, migration and invasion through direct inhibition of XRCC5 in breast cancer. Aging, 2020, 12, 10246-10258.	1.4	16
209	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget, 2016, 7, 55083-55097.	0.8	31
210	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mTOR pathway. Oncotarget, 2016, 7, 60712-60722.	0.8	103
211	Transcriptional signature of lymphoblastoid cell lines of <i>BRCA1</i> and <i>BRCA2</i> and non- <i>BRCA1/2</i> high risk breast cancer families. Oncotarget, 2017, 8, 78691-78712.	0.8	8
212	Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Oncotarget, 2015, 6, 22081-22097.	0.8	20
213	Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells. Oncotarget, 2015, 6, 29637-29650.	0.8	65
214	Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget, 2016, 7, 6891-6901.	0.8	63
215	Expression of Bioinformatically Candidate miRNAs including, miR-576-5p, miR-501-3p and miR-3143, Targeting PI3K Pathway in Triple-Negative Breast Cancer. , 2019, 8, 1646.		4
216	[Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy--©AKT/m-TOR Pathway and Resistance to Cancer Therapy]. Chinese Journal of Lung Cancer, 2018, 21, 63-66.	0.7	6
217	miR-315p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC. Experimental and Therapeutic Medicine, 2020, 19, 375-383.	0.8	11
218	Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World Journal of Clinical Oncology, 2018, 9, 172-179.	0.9	9
219	Dexamethasone Disrupts Cytoskeleton Organization and Migration of T47D Human Breast Cancer Cells by Modulating the AKT/mTOR/RhoA Pathway. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10245-10250.	0.5	19
220	PI3K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer. Re:GEN Open, 2021, 1, 83-91.	0.7	2

#	ARTICLE	IF	CITATIONS
221	New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects. <i>Pharmaceuticals</i> , 2021, 14, 1068.	1.7	27
222	A Network Pharmacology Analysis of the Systems-Perspective Anticancer Mechanisms of the Herbal Drug FDY2004 for Breast Cancer. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110491.	0.2	0
223	Evaluating the influence of Human Umbilical Cord Mesenchymal Stem Cells-derived exosomes loaded with miR-3182 on metastatic performance of Triple Negative Breast Cancer cells. <i>Life Sciences</i> , 2021, 286, 120015.	2.0	24
224	THE ROLE OF PHOSPHATIDYLINOSITOL-3-KINASE IN CARCINOGENESIS. <i>Voprosy Onkologii</i> , 2017, 63, 545-556.	0.1	1
226	Treatment of HER2-Overexpressing Metastatic Breast Cancer. , 2019, , 463-494.		0
228	Upregulation of EPS8L3 is associated with tumorigenesis and poor prognosis in patients with liver cancer. <i>Molecular Medicine Reports</i> , 2019, 20, 2493-2499.	1.1	5
230	Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study. <i>Journal of Biochemical and Molecular Toxicology</i> , 2022, 36, e22938.	1.4	24
231	Pericardial Effusion Caused by an mTOR Inhibitor in a Case of Recurrent Breast Cancer. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2020, 45, 209-213.	0.0	0
233	PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8295-303.	0.5	18
234	MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 368-73.	0.5	16
236	Alnustone inhibits the growth of hepatocellular carcinoma via ROS-mediated PI3K/Akt/mTOR/p70S6K axis. <i>Phytotherapy Research</i> , 2022, 36, 525-542.	2.8	7
237	Beneficial Oxidative Stress-Related trans-Resveratrol Effects in the Treatment and Prevention of Breast Cancer. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 11041.	1.3	12
238	miR-130b suppresses the invasion and migration of prostate cancer via inhibiting DLL1 and regulating the PI3K/Akt pathways. <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 98.	0.8	5
239	<i>Lasiosiphon glaucus</i> a potent ethnobotanical medicinal plant against breast cancer targeting multiple pathways: an invitro study. <i>Advances in Traditional Medicine</i> , 0, , 1.	1.0	0
240	A multidisciplinary approach to optimizing care of patients treated with alpelisib. <i>Breast</i> , 2022, 61, 156-167.	0.9	12
241	Nuances of PFKFB3 Signaling in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e604-e614.	1.1	13
244	Rumex Vesicarius L. extract improves the efficacy of doxorubicin in triple-negative breast cancer through inhibiting Bcl2, mTOR, JNK1 and augmenting p21 expression. <i>Informatics in Medicine Unlocked</i> , 2022, 29, 100869.	1.9	18
245	Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542110731.	0.8	3

#	ARTICLE	IF	CITATIONS
246	Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature. <i>Cureus</i> , 2022, 14, e21970.	0.2	9
247	Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment. <i>Diagnostics</i> , 2022, 12, 394.	1.3	4
248	<i>In silico</i> Prediction on the PI3K/AKT/mTOR Pathway of the Antiproliferative Effect of <i>O. joconostle</i> in Breast Cancer Models. <i>Cancer Informatics</i> , 2022, 21, 117693512210870.	0.9	3
249	Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance. <i>Cardiology Research and Practice</i> , 2022, 2022, 1-14.	0.5	5
250	New and Emerging Targeted Therapies for Advanced Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2288.	1.8	55
251	The Complexity of Response to the Proliferation Agonist and Antagonist Agents, in the Breast Cancer Cell Lines with Various Receptors. <i>Iranian Journal of Pharmaceutical Research</i> , 2022, 21, .	0.3	0
252	Dual PI3K/Akt Inhibitors Bearing Coumarin-Thiazolidine Pharmacophores as Potential Apoptosis Inducers in MCF-7 Cells. <i>Pharmaceuticals</i> , 2022, 15, 428.	1.7	5
253	<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100370.	1.5	17
254	Clinical and molecular characteristics of estrogen receptor- α -positive ultralow risk breast cancer tumors identified by the 70-gene signature. <i>International Journal of Cancer</i> , 2022, 150, 2072-2082.	2.3	7
255	Plant Derived Bioactive Compounds, Their Anti-Cancer Effects and In Silico Approaches as an Alternative Target Treatment Strategy for Breast Cancer: An Updated Overview. <i>Cancers</i> , 2021, 13, 6222.	1.7	20
256	The Discovery of New Drug-Target Interactions for Breast Cancer Treatment. <i>Molecules</i> , 2021, 26, 7474.	1.7	8
258	Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 784985.	1.3	8
262	Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 66.	1.5	3
267	MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells. <i>Endocrine-Related Cancer</i> , 2022, 29, 451-465.	1.6	3
268	Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line. <i>Molecules</i> , 2022, 27, 3661.	1.7	10
269	Biominalization associated alkaline phosphatase as a potential marker of bone metastasis in the patients with invasive breast cancer. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 103340.	1.8	0
270	Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	25
271	Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy. <i>Cancers</i> , 2022, 14, 3374.	1.7	2

#	ARTICLE	IF	CITATIONS
272	The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. <i>Military Medical Research</i> , 2022, 9, .	1.9	5
273	Directed Evolution Enables Simultaneous Controlled Release of Multiple Therapeutic Proteins from Biopolymer-Based Hydrogels. <i>Advanced Materials</i> , 2022, 34, .	11.1	11
274	A Unified Bayesian Framework for Bi-overlapping-Clustering Multi-omics Data via Sparse Matrix Factorization. <i>Statistics in Biosciences</i> , 0, , .	0.6	0
275	Recent Advances in Synthesis and the Anticancer Activity of Benzothiazole Hybrids as Anticancer Agents. , 2022, , 105-166.		0
276	âŸ•ä°Žä•ç»†èfžæ•æ°çš,,ç™Œç—†ââŒé©±âš'æ"jâ•-è†â^«æ-1æ³•. <i>Scientia Sinica Informationis</i> , 2022, , .	0.2	0
278	Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. <i>Biomedicines</i> , 2022, 10, 1914.	1.4	5
279	Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	8
280	XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113537.	2.5	9
281	Redox Signaling. , 2022, , 3435-3455.		0
282	Mechanistic and Therapeutic Crosstalk of Lipid Peroxidation in Oxidative Stress and Breast Cancer. , 2022, , 3457-3475.		0
283	Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 4234.	1.7	2
284	SDC4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer risk. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
285	<sc>6â€Methoxydihydroanguinarine</sc> induces apoptosis and autophagy in breast cancer <sc>MCF</sc>â€7 cells by accumulating <sc>ROS</sc> to suppress the <sc>PI3K</sc>/<sc>AKT</sc>/<sc>mTOR</sc> signaling pathway. <i>Phytotherapy Research</i> , 2023, 37, 124-139.	2.8	6
286	Understanding the Polyamine and mTOR Pathway Interaction in Breast Cancer Cell Growth. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 51.	1.3	7
287	A Potential Anticancer Mechanism of Finger Root (<i>Boesenbergia rotunda</i>) Extracts against a Breast Cancer Cell Line. <i>Scientifica</i> , 2022, 2022, 1-17.	0.6	5
288	Myokines derived from contracting skeletal muscle suppress anabolism in MCF7 breast cancer cells by inhibiting mTOR. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	3
289	Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway. , 2022, 39, .		12
290	Subpathway Analysis of Transcriptome Profiles Reveals New Molecular Mechanisms of Acquired Chemotherapy Resistance in Breast Cancer. <i>Cancers</i> , 2022, 14, 4878.	1.7	4

#	ARTICLE	IF	CITATIONS
291	mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12470.	1.8	6
292	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. <i>Cancers</i> , 2022, 14, 5206.	1.7	14
293	Predicting clinical response to everolimus in ER+ breast cancers using machine-learning. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
295	Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients. <i>Heliyon</i> , 2022, , e11396.	1.4	0
296	LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway. <i>Cancer Biology and Therapy</i> , 2022, 23, 1-13.	1.5	7
297	Evaluation of ⁶⁸ Ga-Radiolabeled Peptides for HER2 PET Imaging. <i>Diagnostics</i> , 2022, 12, 2710.	1.3	1
298	Network pharmacology based investigation on the mechanism of tetrandrine against breast cancer. <i>Phytomedicine Plus</i> , 2023, 3, 100381.	0.9	0
299	The combination of <i>Elephantopus scaber</i> and <i>Phaleria macrocarpa</i> leaves extract promotes anticancer activity via downregulation of ER-1±, Nrf2 and PI3K/AKT/mTOR pathway. <i>Journal of Ayurveda and Integrative Medicine</i> , 2022, 13, 100674.	0.9	1
302	Investigating the Function of Human Jumping Translocation Breakpoint Protein (hJTB) and Its Interacting Partners through In-Solution Proteomics of MCF7 Cells. <i>Molecules</i> , 2022, 27, 8301.	1.7	5
303	Cancer Stem Cellsâ€”The Insight into Non-Coding RNAs. <i>Cells</i> , 2022, 11, 3699.	1.8	2
304	Synthesis, molecular docking, and in-vitro studies of pyrimidine-2-thione derivatives as antineoplastic agents via potential RAS/PI3K/Akt/JNK inhibition in breast carcinoma cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
305	<scp>RMI2</scp> is a novel prognostic and predictive biomarker for breast cancer. <i>Cancer Medicine</i> , 2023, 12, 8331-8350.	1.3	3
306	PI3Kâ€”AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. <i>Biomolecules</i> , 2023, 13, 93.	1.8	16
307	OGT controls mammalian cell viability by regulating the proteasome/mTOR/ mitochondrial axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	6
308	Using publicly available datasets to identify population-based transcriptomic landscape contributing to the aggressiveness of breast cancer in young women. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
309	Combination of Conventional Drugs with Biocompounds Derived from Cinnamic Acid: A Promising Option for Breast Cancer Therapy. <i>Biomedicines</i> , 2023, 11, 275.	1.4	5
310	Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway <i>in vitro</i> and <i>in vivo</i>. <i>Acta Pharmaceutica</i> , 2023, 73, 75-90.	0.9	1
311	Upstreaming and Downstreaming Regulators and Associated Signaling Transduction Pathways of AKT/PKB: A Molecular Gateway to Progressive Carcinoma. <i>Asian Journal of Biology</i> , 0, , 8-15.	0.2	0

#	ARTICLE	IF	CITATIONS
312	Brazilein inhibits epithelial-mesenchymal transition (EMT) and programmed death ligand 1 (PD-L1) expression in breast cancer cells. <i>International Immunopharmacology</i> , 2023, 118, 109988.	1.7	1
313	Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. <i>Biochemical Pharmacology</i> , 2023, 212, 115545.	2.0	8
314	Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis. <i>Life Sciences</i> , 2023, 323, 121662.	2.0	6
315	Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. <i>Cancers</i> , 2023, 15, 1320.	1.7	13
316	Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
317	Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. <i>Cancers</i> , 2023, 15, 1582.	1.7	4
318	Proteomics analysis of human breast milk by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) coupled with mass spectrometry to assess breast cancer risk. <i>Electrophoresis</i> , 2023, 44, 1097-1113.	1.3	1
319	Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. <i>Investigational New Drugs</i> , 0, , .	1.2	0
320	Anthocyanins Reduce Cell Invasion and Migration through Akt/mTOR Downregulation and Apoptosis Activation in Triple-Negative Breast Cancer Cells: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 2300.	1.7	2
322	Nanomedicine Technologies for Diagnosis and Treatment of Breast Cancer. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 671-682.	2.5	7
358	Oncolytic Virotherapy Against Breast Cancer. , 2023, , .		0
369	Anti-breast cancer potential analysis of phytochemicals in <i>Selaginella doederleinii</i> Hieron ethanolic extract through in silico study. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0